NORTHLAND

NORTHLAND

Language

The Phase III clinical trial results of Donaperminogene Seltoplasmid Injection—a gene therapy drug originally developed in China—were presented at LINC2026, a top international academic forum.

发布时间：2026-01-30

From January 27 to 30, 2026, the Leipzig Interventional Vascular Conference (LINC 2026)—renowned as the “global benchmark for vascular intervention therapy”—will be held in Leipzig, Germany. At the conference, Professor Di Xiao from the Department of Vascular Surgery at Peking Union Medical College Hospital, representing the research team, officially released the pivotal data from the Phase III clinical trial (HOPE CLTI-2 study) of “Sedominji Injection,” an innovative gene therapy drug independently developed by our company, for the treatment of chronic limb-threatening ischemia (CLTI) of the lower limbs. This marks the first time that a Chinese-originated gene therapy drug has presented large-scale clinical research findings on an internationally leading academic platform such as LINC.

28

2026-01

The holding subsidiary’s cyclosporine eye drops have been approved for clinical trials, accelerating its strategic transformation toward high-end products.

发布时间：2026-01-28

Recently, Huonland, a subsidiary of NORTHLAND Holdings, successfully passed the review by the National Medical Products Administration for its 0.05% cyclosporine eye drops (II), which were filed under Category 3 of chemical products, and received the "Drug Clinical Trial Approval Notice" (Notice No.: 2026LP00228). This marks another significant milestone in Huienland's strategic upgrade—from a generic drug manufacturer to a high-end ophthalmic formulation R&D enterprise.

18

2025-12

Donaperminogene Seltoplasmid Injection Makes Its Debut at the Huimai Vascular Disease Forum—Innovative Therapy Offers New Approaches for Clinical Treatment of CLI

发布时间：2025-12-18

From December 12 to 13, 2025, the Inaugural Conference of the Specialized Committee on Arteriovenous and Peripheral Vascular Diseases of the China Association for Geriatric Health Care, together with the Huimei Vascular Disease Forum, was successfully held in Hefei, Anhui Province. The conference was organized by the China Association for Geriatric Health Care and co-organized by the Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and the Second Affiliated Hospital of Anhui Medical University. The event brought together top vascular disease experts from across China, focusing on cutting-edge developments in vascular diseases, jointly exploring China’s comprehensive system for the prevention and treatment of vascular diseases, and working together to build a robust defense for the vascular health of the elderly.

11

2025-12

The discussion meeting on the Phase IIc clinical trial protocol for Recombinant Human Thymosin β4 Injection (NL005) was successfully held.

发布时间：2025-12-11

On December 9, 2025, the "Summary Meeting of Phase IIb Clinical Trial and Discussion on Phase IIc Clinical Trial Protocol for Recombinant Human Thymosin β4 Injection (NL005)," hosted by Beijing Northland Biotechnology Co., Ltd., was successfully held in Beijing. The meeting adopted a hybrid online-and-offline format, bringing together more than 20 experts from the fields of cardiovascular medicine and magnetic resonance imaging, representing over 10 clinical research centers across China, as well as representatives from the sponsor and the CRO team. The attending experts conducted in-depth scientific discussions and feasibility assessments centered on the previous research findings of NL005 and the design of the Phase IIc clinical trial protocol.

08

2025-12

Donaperminogene Seltoplasmid Injection Shines at the First Academic Annual Conference of the Vascular Surgery Branch of the National Association for Health Industry Enterprise Management

发布时间：2025-12-08

From December 5 to 6, 2025, the inaugural Academic Annual Conference of the Vascular Surgery Branch of the National Health Industry Enterprise Management Association, together with the 2025 Academic Symposium on New Advances in the Diagnosis and Treatment of Diabetic Foot, will be grandly held in Beijing. Co-organized by the Zhongguancun Precision Medicine Foundation and other institutions, the conference has drawn together top experts and scholars from various disciplines—including vascular surgery, wound healing, and endocrinology—providing a platform for them to discuss the cutting-edge developments in their fields. At this conference, Mr. Xu Songshan, Chairman of our company, was appointed as a director of the Vascular Surgery Branch of the National Health Industry Enterprise Management Association, thanks to his profound industry background.

07

2025-12

Researchers involved in the Phase III clinical trial of Donaperminogene Seltoplasmid Ingection have been invited to attend the LINC Conference in Germany and deliver a keynote presentation.

发布时间：2025-12-07

Recently, Dr. Xi Xiao from the Department of Vascular Surgery at Peking Union Medical College Hospital received an invitation from the organizers of LINC (Leipzig Interventional Course) to attend the annual LINC conference in Leipzig, Germany, on January 29, 2026, and deliver a keynote presentation. Dr. Xi Xiao is one of the principal investigators of the Phase III clinical trial for our company’s innovative gene therapy drug, “Donaperminogene Seltoplasmid Ingection.” At the LINC conference, he will give a keynote speech to comprehensively present the clinical research findings on “Donaperminogene Seltoplasmid Ingection” for the treatment of critical limb ischemia (CLI)—a severe lower-limb vascular disease. He will share with global vascular surgeons and peers the progress and achievements made in the development of this China-originated, clinically-led innovative gene therapy drug, as well as the latest updates on its clinical trials.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

Follow Us

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

WeChat Mini Program

Web site

WeChat Official Account

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license

Powered by 300.cn  Privacy Policy